Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 in second-line gastrointestinal cancers
ChiCTR2400089007Phase 2Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sacituzumab tirumotecan in colorectal adenocarcinoma, pancreatic adenocarcinoma (PDAC), biliary cancer and 2 more (3 arms), sponsored by Union Hospital. Primary endpoint: Objective response rate (ORR). Planned start Aug 2024; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
colorectal adenocarcinomapancreatic adenocarcinoma (PDAC)biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2400089007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089007.